Browse News
Filter News
Found 40 articles
-
Enveda Biosciences Announces Therapeutic Advisory Board Chaired by Nicholas Saccomano, Ph.D.
1/10/2024
Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.
-
ImmunoBrain Checkpoint Announces Expansion of Board of Directors with Appointment of James M. Mackay, Ph.D.
8/15/2023
ImmunoBrain Checkpoint Inc.today announced the appointment of James M. Mackay , Ph.D., to the Board of Directors. Mackay brings decades of biopharma leadership experience to the Company's Board.
-
The company’s pipeline changes come as it weathered a nearly 30% decline in first-quarter revenues due to a slowdown in its COVID-19 business.
-
Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel
3/22/2023
Capstan Therapeutics, Inc. today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
-
Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.
-
Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Company
2/10/2023
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced that, due to safety findings in the ongoing Phase 2 clinical trials, it has discontinued the RIST4721 development program in order to protect patient safety.
-
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
-
Aristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs Progress
11/2/2022
Aristea Therapeutics announced the appointments of three experienced drug development experts to key positions as it works to progress and expand its clinical pipeline: Himanshu Patel, D.O., as Executive Medical Director, Jennifer Barnes, Ph.D., as Senior Director, Clinical Science, and Walter Frank Eng, PharmD, as Associate Director, Clinical Science.
-
Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurativa
8/30/2022
Aristea Therapeutics today announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa (HS).
-
Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer
8/24/2022
Aristea Therapeutics today announced the appointment of Mark Gergen and Daniel O'Connell , M.D., Ph.D., to the Board of Directors.
-
Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
6/30/2022
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced it has dosed its first subject in the open-label extension (OLE) for its Phase 2b trial of RIST4721 in palmoplantar pustulosis (PPP).
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosis
3/28/2022
Aristea Therapeutics today announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721.
-
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
-
Aristea Therapeutics Announces Key Leadership Appointments to Advance Its Clinical Pipeline
1/13/2022
Aristea Therapeutics today announced the appointment of Ciara Kennedy as Aristea Therapeutics' Chair of the Board of Directors and Fabio Magrini as Executive Medical Director.
-
Aristea Therapeutics to Present at Biotech Showcase 2022 and H.C. Wainwright Bioconnect Conferences
1/6/2022
Aristea Therapeutics, a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, announced that James Mackay, Ph.D., President and CEO, will participate virtually in the following investor conferences in January.
-
Arena Reports Third Quarter Financial Results and Key Program Updates
11/4/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
-
It's a New Hybrid World for Biopharma
9/20/2021
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.” -
Aristea Therapeutics to Present at Upcoming Investor Conferences
9/20/2021
Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October: